Acute Myeloid Leukemia: From Diagnosis to Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 3303
Special Issue Editor
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy and the most common acute leukemia in adults. For many years, the standard treatment for AML consisted of intensive and prolonged chemotherapy with a combination of cytarabine and an anthracycline, commonly referred to as “7+3”. In addition to the toxicities and lengthy, frequent hospitalizations associated with this regimen, most patients, including those with "favorable" risk factors experienced frequent relapses and short survival times. Over the past two decades, the genetic and molecular underpinnings of AML have become better defined, thereby paving the way for refinements in the disease classification, risk-stratification, and development of newer and better tolerated treatment options. As such, the diagnosis and treatment paradigm for AML has become more personalized, but also more complex. In this Special Issue, we focus on the most recent updates regarding AML diagnosis and classification, as well as on newest therapies for AML that are currently available and those under development. We will discuss factors that are considered when tailoring a treatment decision, both in newly diagnosed and relapsed/refractory settings, including the role of allogeneic stem cell transplant and the current state of cellular therapies.
In this Special Issue, original research articles and reviews within the scope of the topics described above are welcome.
I look forward to receiving your contributions.
Dr. Bhavana Bhatnagar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- treatment
- risk factors
- classification
- diagnosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
